Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 15/20 | 0.39 |
| ▸ | GLS | O94925 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4875960 | 1.00 | AOC3 (0.39) | AOC3GLSMEN1CYP1A2CYP2C9 | |
| SCHEMBL4878076 | 0.91 | MEN1 (0.44) | AOC3MEN1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL4878066 | 0.91 | MEN1 (0.44) | AOC3MEN1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL4872994 | 0.87 | AOC3 (0.43) | AOC3GLSCYP17A1 | |
| SCHEMBL4872983 | 0.87 | AOC3 (0.43) | AOC3GLSCYP17A1 | |
| SCHEMBL3933137 | 0.87 | GLS (0.46) | AOC3GLSCYP17A1 | |
| SCHEMBL3931427 | 0.86 | AOC3 (0.37) | AOC3GLSCYP17A1 | |
| SCHEMBL3931434 | 0.86 | AOC3 (0.37) | AOC3GLSCYP17A1 | |
| SCHEMBL3931429 | 0.86 | AOC3 (0.37) | AOC3GLSCYP17A1 | |
| SCHEMBL4871293 | 0.86 | MEN1 (0.36) | AOC3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1608365-B1 | METHOD FOR TREATING VASCULAR HYPERPERMEABLE DISEASE | R TECH UENO LTD (JP) | 2013-10-02 | — | — | EP | disclosed |
| US-7442715-B2 | Thiazole derivatives | ASTELLAS PHARMA INC. (JP) | 2008-10-28 | — | — | US | disclosed |
| US-20080119462-A1 | METHOD FOR TREATING VASCULAR HYPERPERMEABLE DISEASE | SUCAMPO AG (CH) | 2008-05-22 | — | — | US | disclosed |
| US-20060276521-A1 | Thiazole derivatives | ASTELLAS PHARMA INC. (JP) | 2006-12-07 | — | — | US | disclosed |
| US-7125901-B2 | Thiazole derivatives | ASTELLAS PHARMA INC. (JP) | 2006-10-24 | — | — | US | disclosed |
| US-20060229346-A1 | Method for treating vascular hyperpermeable disease | SUCAMPO AG (CH) | 2006-10-12 | — | — | US | disclosed |
| US-20060128770-A1 | Thiazole derivatives | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2006-06-15 | — | — | US | disclosed |
| US-20040259923-A1 | Compound useful as cellular adhesion protein and as antiedemic agent | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2004-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119462-A1 | METHOD FOR TREATING VASCULAR HYPERPERMEABLE DISEASE | VCAM1, ICAM1, VAPB | AOC3 202/4885GLS 3490/4885MEN1 3711/4885 |
| US-20060276521-A1 | Thiazole derivatives | VCAM1, ICAM1, TXNL1 | AOC3 782/4885GLS 2685/4885MEN1 2478/4885 |
| US-20060229346-A1 | Method for treating vascular hyperpermeable disease | VCAM1, VAPB, ICAM1 | AOC3 85/4885GLS 3054/4885MEN1 3836/4885 |
| US-20060128770-A1 | Thiazole derivatives | VCAM1, ICAM1, TXNL1 | AOC3 782/4885GLS 2685/4885MEN1 2478/4885 |
| US-20040259923-A1 | Compound useful as cellular adhesion protein and as antiedemic agent | VCAM1, ICAM1, VAPB | AOC3 590/4885GLS 2577/4885MEN1 3241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.